Chr	Start	End	Ref	Alt	Ref.Gene	Func.refGene	ExonicFunc.refGene	Gene.ensGene	avsnp150	clinvar: Clinvar	VIC: VIC and Evidence	AAChange.ensGene	AAChange.refGene	AAChange.knownGene	Freq_ExAC_ALL	Freq_esp6500siv2_all	Freq_1000g2015aug_all	Freq_gnomAD_AF	FATHMM_pred	CADD_phred	SIFT_score	GERP++_RS	Polyphen2_HDIV_pred	dbscSNV_ADA_SCORE	dbscSNV_RF_SCORE	Interpro_domain	MetaSVM_score	MutationTaster_pred	Freq_ExAC_POPs	Freq_gnomAD_exome_POPs	OMIM	Phenotype_MIM	OrphaNumber	Orpha	cgi_info	civic_info	Otherinfo
7	55259515	55259515	T	G	EGFR	exonic	nonsynonymous SNV	ENSG00000146648	rs121434568	 clinvar: 7 	 VIC: Uncertain significance EVS=[0, 1, NONE, NONE, 0, 0, 2, 2, 2, NONE] 	ENSG00000146648:ENST00000455089:exon20:c.T2438G:p.L813R,ENSG00000146648:ENST00000275493:exon21:c.T2573G:p.L858R,ENSG00000146648:ENST00000454757:exon21:c.T2414G:p.L805R	EGFR:NM_001346941:exon15:c.T1772G:p.L591R,EGFR:NM_001346897:exon20:c.T2438G:p.L813R,EGFR:NM_001346899:exon20:c.T2438G:p.L813R,EGFR:NM_001346898:exon21:c.T2573G:p.L858R,EGFR:NM_001346900:exon21:c.T2414G:p.L805R,EGFR:NM_005228:exon21:c.T2573G:p.L858R	EGFR:uc022ado.1:exon2:c.T278G:p.L93R,EGFR:uc010kzg.2:exon20:c.T2438G:p.L813R,EGFR:uc022adn.1:exon20:c.T2438G:p.L813R,EGFR:uc003tqk.3:exon21:c.T2573G:p.L858R,EGFR:uc011kco.2:exon21:c.T2414G:p.L805R,EGFR:uc022adm.1:exon21:c.T2573G:p.L858R	.	.	.	7	D	33	0.0	5.71	D	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	0.987	D	AFR:., AMR:., FIN., NFE:., SAS:., OTH:.	AFR:7, AMR:7, ASJ7, EAS7, FIN7, NFE:7, SAS:7, OTH:7	131550	211980;616069;	294023; 	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~null~	.	EGFR, L858R, Lung Adenocarcinoma, Gefitinib, Predictive, Does Not Support, B, Reduced Sensitivity, In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704)., Urata et al., 2016, J. Clin. Oncol.
1	241663903	241663904	GA	-	FH	intronic	.	ENSG00000091483	rs879069854	 clinvar: 1 	 VIC: Strong clinical significance EVS=[2, 1, 1, NONE, 1, 2, 2, 2, 2, 1] 	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	AFR:., AMR:., FIN., NFE:., SAS:., OTH:.	AFR:1, AMR:1, ASJ1, EAS1, FIN1, NFE:1, SAS:1, OTH:1	136850	150800;606812;	24;523; 	24|Fumarase deficiency|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|606812 ~523|Familial leiomyomatosis and renal cell cancer<br>Familial leiomyomatosis cutis et uteri<br>Familial leiomyomatosis with renal carcinoma<br>Familial multiple cutaneous leiomyomas<br>HLRCC<br>Hereditary leiomyomatosis<br>Hereditary leiomyomatosis with renal carcinoma<br>Hereditary multiple cutaneous leiomyomas<br>MCUL<br>Multiple cutaneous and uterine leiomyomas<br>Reed syndrome|Unknown|Autosomal dominant|Adolescent<br>Adult<br>Elderly|150800 ~null~	.	.
17	7578378	7578409	ATCTGAGCAGCGCTCATGGTGGGGGCAGCGCC	-	TP53	exonic	frameshift deletion	ENSG00000141510	.	 clinvar: 17 	 VIC: Strong clinical significance EVS=[2, 1, 1, NONE, 1, 2, 2, 2, 2, 1] 	ENSG00000141510:ENST00000509690:exon2:c.125_156del:p.R42fs,ENSG00000141510:ENST00000359597:exon4:c.521_552del:p.R174fs,ENSG00000141510:ENST00000413465:exon4:c.521_552del:p.R174fs,ENSG00000141510:ENST00000514944:exon4:c.242_273del:p.R81fs,ENSG00000141510:ENST00000269305:exon5:c.521_552del:p.R174fs,ENSG00000141510:ENST00000420246:exon5:c.521_552del:p.R174fs,ENSG00000141510:ENST00000445888:exon5:c.521_552del:p.R174fs,ENSG00000141510:ENST00000455263:exon5:c.521_552del:p.R174fs	TP53:NM_001126115:exon1:c.125_156del:p.R42fs,TP53:NM_001126116:exon1:c.125_156del:p.R42fs,TP53:NM_001126117:exon1:c.125_156del:p.R42fs,TP53:NM_001276697:exon1:c.44_75del:p.R15fs,TP53:NM_001276698:exon1:c.44_75del:p.R15fs,TP53:NM_001276699:exon1:c.44_75del:p.R15fs,TP53:NM_001126118:exon4:c.404_435del:p.R135fs,TP53:NM_000546:exon5:c.521_552del:p.R174fs,TP53:NM_001126112:exon5:c.521_552del:p.R174fs,TP53:NM_001126113:exon5:c.521_552del:p.R174fs,TP53:NM_001126114:exon5:c.521_552del:p.R174fs,TP53:NM_001276695:exon5:c.404_435del:p.R135fs,TP53:NM_001276696:exon5:c.404_435del:p.R135fs,TP53:NM_001276760:exon5:c.404_435del:p.R135fs,TP53:NM_001276761:exon5:c.404_435del:p.R135fs	TP53:uc002gii.2:exon1:c.44_75del:p.R15fs,TP53:uc010cnf.2:exon1:c.44_75del:p.R15fs,TP53:uc010cng.2:exon1:c.44_75del:p.R15fs,TP53:uc002gio.3:exon2:c.125_156del:p.R42fs,TP53:uc002gig.1:exon4:c.521_552del:p.R174fs,TP53:uc002gih.3:exon4:c.521_552del:p.R174fs,TP53:uc002gin.3:exon4:c.242_273del:p.R81fs,TP53:uc010vug.3:exon4:c.404_435del:p.R135fs,TP53:uc031qyq.1:exon4:c.404_435del:p.R135fs,TP53:uc002gij.3:exon5:c.404_435del:p.R135fs,TP53:uc002gim.3:exon5:c.521_552del:p.R174fs,TP53:uc010cnh.2:exon5:c.521_552del:p.R174fs,TP53:uc010cni.2:exon5:c.521_552del:p.R174fs	.	.	.	17	.	.	.	.	.	.	.	.	.	.	AFR:., AMR:., FIN., NFE:., SAS:., OTH:.	AFR:17, AMR:17, ASJ17, EAS17, FIN17, NFE:17, SAS:17, OTH:17	191170	114480;114500;114550;137800;151623;202300;259500;260350;260500;607107;614740;	150;251899;2807;1333;668;1501;524;182067;251627;251630;301;360;94;449;88673;227535; 	150|-|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|161550 607107 617075 ~251899|-|1-9 / 1 000 000|Autosomal dominant|Childhood|260500 ~2807|CPP<br>Choroid plexus papilloma|-|-|All ages|260500 ~1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~668|Osteogenic sarcoma|1-9 / 100 000|-|Childhood|259500 ~1501|-|1-9 / 1 000 000|Not applicable|Childhood|202300 ~524|-|1-9 / 100 000|Autosomal dominant|All ages|151623 609265 609266 ~182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~251627|-|-|Not applicable|All ages|137800 616568 ~251630|-|-|Not applicable|Adult|137800 616568 ~301|-|1-9 / 100 000|-|All ages|137800 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~94|Astrocytic tumor|1-9 / 100 000|-|All ages|137800 ~449|-|1-9 / 1 000 000|Not applicable|Neonatal<br>Infancy<br>Childhood|114550 ~88673|HCC|1-5 / 10 000|Not applicable|All ages|114550 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~null~	.	.
